Skip to content
Screener

Inhibrx Biosciences, Inc. INBX Cash & Equivalents

Cash & Equivalents at other companies

Pfizer logo
PfizerPFE
$1.76B+18.8%
Rogers Corporation logo
Rogers CorporationROG
$181.4M+15.4%
Merck & Co. logo
Merck & Co.MRK
$6.89B-14.6%
Gilead Sciences logo
Gilead SciencesGILD
$3.18B-38.2%
Nuvation Bio logo
Nuvation BioNUVB
$258.6M+4.3%
Eikon Therapeutics, Inc. logo
Eikon Therapeutics, Inc.EIKN
$161.15M-21.2%

Other financials

Income statement

See full
Revenue--100%
Operating income-$30.9M+27.9%
Net income-$33.4M+22.8%
EPS (diluted)-$2.15+23.2%

Balance sheet

See full
Total debt$180.9M+69.8%
Total equity-$21.0M-122%
Total assets$184.0M-24.2%

Cash flow

See full
Operating cash flow-$38.0M-5.9%
CapEx--100%
Free cash flow-$38.0M-5.9%

Valuation

See full
Market cap$1.26B+314%
Enterprise value$1.28B+471%

Profitability

See full
Operating margin-10,386.5%-5,025pp
Net margin-10,773.5%-878,492pp
FCF margin-9,986.5%-4,727pp

Returns & leverage

See full
Return on equity-197.8%-2,158pp
Debt / equity13.4×+13.3×
Current ratio6.5×+1.3×

Where this comes from

Reported directly by Inhibrx Biosciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.

The source filing: Inhibrx Biosciences, Inc.’s 10-Q, filed May 14, 2026.

Filed
May 14, 2026, 4:02 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0002007919-26-000027
Line itemTHREE MONTHS ENDEDMARCH 31, 2026THREE MONTHS ENDEDMARCH 31, 2025
Net cash provided by financing activities75,46399,840
Net increase in cash and cash equivalents37,43763,924
Cash and cash equivalents at beginning of period124,220152,596
Cash and cash equivalents at end of period$161,657$216,520
Supplemental disclosure of cash flow information
Cash paid for interest$2,778$1,299
Cash paid for income taxes——
Supplemental schedule of non-cash investing and financing activities

Item 1. Financial Statements (unaudited)

FAQ

What is Inhibrx Biosciences, Inc.'s cash & equivalents?
Inhibrx Biosciences, Inc. (INBX) reported cash & equivalents of $161.66M in Q1 2026.
How has Inhibrx Biosciences, Inc.'s cash & equivalents changed year-over-year?
Inhibrx Biosciences, Inc.'s cash & equivalents decreased by 25.3% year-over-year, from $216.52M to $161.66M.
What is the long-term trend for Inhibrx Biosciences, Inc.'s cash & equivalents?
Over 3 years (2022 to 2025), Inhibrx Biosciences, Inc.'s cash & equivalents has grown at a -23.2% compound annual growth rate (CAGR), from $273.87M to $124.22M.
What does cash & equivalents mean?
Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.

Ask your AI about Inhibrx Biosciences, Inc.'s cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude